

28th August, 2026

(1) BSE Limited
Listing Department,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai 400 001

Scrip Code: 500087

(2) National Stock Exchange of India Limited
Listing Department
Exchange Plaza, 5th floor,
Plot no. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai - 400 051

Scrip Code: CIPLA

(3) SOCIETE DE LA BOURSE DE LUXEMBOURG
Societe Anonyme
35A Boulevard Joseph II,
L-1840 Luxembourg

Dear Sir/Madam,

Sub: Update on USFDA inspection at InvaGen manufacturing facility in Central Islip, Long Island, NY, USA

Dear Sir/Madam,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and further to our intimation dated 18th July, 2026 regarding the United States Food and Drug Administration (USFDA) inspection conducted at the Unit 3 manufacturing facility of InvaGen Pharmaceuticals Inc. (wholly owned subsidiary of the Company) located in Central Islip, Long Island, New York, USA, from 13th July, 2026 to 17th July, 2026 (EDT), we hereby notify that the USFDA vide communication dated 28th August, 2026 has classified the above referred inspection as Voluntary Action Indicated (VAI).

Kindly take the above information on record.

Yours faithfully,
For Cipla Limited

Rajendra Chopra
Company Secretary

Prepared by: Simona Dsouza